Nephrology Dialysis Transplantation, Vol 13, Issue 5 1200-1205, Copyright © 1998 by Oxford University Press
F Kokot, A Wiecek, J Mesjasz, M Adamczak and U Spiechowicz
Background: In patients with chronic renal failure,
rHuEpo therapy ameliorates anaemia and improves wellbeing, exercise
tolerance, and appetite. Both leptin and neuropeptide Y play an important
role in regulation of appetite and energy balance in humans.
Methods: The present study aimed to assess the
influence of 12 months rHuEpo therapy on plasma leptin and neuropeptide Y
concentrations in 15 haemodialysed patients (HDP) (6F, 9M; mean age
4.8±2.9 years; mean BMI 23.6±1.1
kg/m2; mean duration of HD 3.3±0.6
months) (Epo group). A second group (no-Epo group) consisted of 17 HDP (9F,
8M; mean age 44±3.2 years; mean BMI 24.3±1.0
kg/m2; mean duration of HD 2.5±0.4 months
not treated with rHuEpo for 12 months. Basal plasma leptin and neuropeptide
Y concentrations were estimated by RIA at the beginning and after 3, 6, 9
and 12 months of rHuEpo therapy (Epo group) or clinical observation (No-Epo
group). The control group consisted of 30 healthy subjects (15 females, 15
males, mean age-38.2±1.7 years, mean BMI 24.7±0.7
kg/m2). Results: Baseline
plasma leptin concentrations in HDP were higher, although statistically not
significant than leptinaemia in healthy subjects. After 3, 6, and 12 months
of rHuEpo therapy plasma leptin concentrations were significantly lower
than at the beginning of the study. Baseline plasma neuropeptide Y
concentrations in HDP did not differ significantly from controls. After 3
and 6 months of the study period plasma neuropeptide Y concentrations
increased significantly in patients of both the Epo and No-Epo group. This
increase was, however significantly higher in rHuEpo-treated than in
untreated patients. Conclusions: (1) rHuEpo treatment
in haemodialysed patients with chronic renal failure is followed by a
significant decline of leptinaemia and disappearance of the physiological
positive BMI/leptinaemia relationship. (2) Suppression of leptinaemia
induced by rHuEpo may be of clinical relevance in haemodialysed patients
with chronic renal failure. Key words: anaemia;
erythropoietin; haemodialysis; leptin; neuropeptide Y; uraemia
ORIGINAL ARTICLES
Influence of long-term recombinant human erythropoietin (rHuEpo) therapy on plasma leptin and neuropeptide Y concentration in haemodialysed uraemic patients
Department of Nephrology, Endocrinology and Metabolic Diseases, Silesian University School of Medicine, Francuska 20/24 Str., PL-40-027 Katowice, Poland; Division of Nephrology, Coal Miners Hospital, Bytom, Poland; Corresponding author
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. P. Davis, R. Dreicer, D. Walsh, R. Lagman, and S. B. LeGrand Appetite and Cancer-Associated Anorexia: A Review J. Clin. Oncol., April 15, 2004; 22(8): 1510 - 1517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zoccali, F. Mallamaci, G. Tripepi, F. A. Benedetto, S. Cutrupi, S. Parlongo, L. S. Malatino, G. Bonanno, G. Seminara, F. Rapisarda, et al. Adiponectin, Metabolic Risk Factors, and Cardiovascular Events among Patients with End-Stage Renal Disease J. Am. Soc. Nephrol., January 1, 2002; 13(1): 134 - 141. [Abstract] [Full Text] [PDF]
|
|